CD8A and neoplasm: Inhibiting Gln flux by SLC1A5, SLC38A2, and SLC7A5 transporters with the V9302 small molecule antagonist boosts the tumor infiltration of CD8+ T cells in syngeneic breast cancer models and sensitizes experimental tumors to the programmed death-1 receptor 1 (PD-1) blockade [96].